Matinas BioPharma Holdings, Inc. MTNB

Company Overview

Matinas BioPharma Holdings, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing lipid nanocrystal (LNC) platform-based therapeutics and drug delivery technologies. The company operates within the biotechnology and pharmaceutical industries, with a strategic emphasis on improving the oral delivery, tolerability, and bioavailability of medicines that are traditionally difficult to administer. Matinas has historically concentrated on infectious diseases, oncology-supportive therapies, and lipid-based drug formulation technologies. Its primary value proposition centers on proprietary lipid nanocrystal delivery systems designed to enable oral administration of compounds that are otherwise delivered intravenously or associated with significant toxicity.

The company’s core business activities have revolved around advancing its proprietary LNC Platform Technology and related product candidates, including formulations involving amphotericin B and omega-3-derived therapeutics. Matinas was founded through the combination and evolution of predecessor biotechnology entities and became publicly traded on the NYSE American under the ticker MTNB. Over time, the company shifted from a broader lipid therapeutic focus toward platform-driven pharmaceutical delivery applications, seeking strategic collaborations with larger pharmaceutical companies interested in reformulating existing drugs using oral lipid nanocrystal technology.